Nordea Investment Management AB Has $73.97 Million Position in Abbott Laboratories $ABT

Nordea Investment Management AB raised its stake in Abbott Laboratories (NYSE:ABT) by 79.0% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 589,519 shares of the healthcare product maker’s stock after buying an additional 260,089 shares during the quarter. Nordea Investment Management AB’s holdings in Abbott Laboratories were worth $73,967,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. State Street Corp grew its holdings in shares of Abbott Laboratories by 0.9% during the 2nd quarter. State Street Corp now owns 78,354,270 shares of the healthcare product maker’s stock valued at $10,656,964,000 after acquiring an additional 689,517 shares in the last quarter. Capital International Investors raised its holdings in shares of Abbott Laboratories by 2.5% during the third quarter. Capital International Investors now owns 61,614,739 shares of the healthcare product maker’s stock worth $8,251,974,000 after acquiring an additional 1,478,076 shares in the last quarter. Norges Bank acquired a new stake in Abbott Laboratories during the second quarter valued at $3,026,180,000. Massachusetts Financial Services Co. MA grew its stake in Abbott Laboratories by 5.8% in the third quarter. Massachusetts Financial Services Co. MA now owns 15,096,907 shares of the healthcare product maker’s stock valued at $2,022,080,000 after purchasing an additional 821,325 shares in the last quarter. Finally, Invesco Ltd. increased its position in Abbott Laboratories by 51.0% in the 3rd quarter. Invesco Ltd. now owns 13,951,907 shares of the healthcare product maker’s stock worth $1,868,718,000 after purchasing an additional 4,713,135 shares during the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, Director Daniel J. Starks acquired 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 4th. The stock was acquired at an average price of $108.73 per share, with a total value of $1,087,300.00. Following the transaction, the director owned 6,738,817 shares of the company’s stock, valued at approximately $732,711,572.41. This trade represents a 0.15% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP John A. Jr. Mccoy sold 585 shares of the stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $67,614.30. Following the sale, the vice president owned 24,628 shares of the company’s stock, valued at approximately $2,846,504.24. The trade was a 2.32% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 3,055 shares of company stock worth $353,097. Corporate insiders own 0.46% of the company’s stock.

Abbott Laboratories Stock Down 0.6%

Shares of ABT stock opened at $104.87 on Tuesday. The stock’s 50 day simple moving average is $112.36 and its 200 day simple moving average is $122.77. Abbott Laboratories has a twelve month low of $104.10 and a twelve month high of $139.06. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.18 and a current ratio of 1.58. The company has a market capitalization of $182.65 billion, a price-to-earnings ratio of 28.19, a PEG ratio of 1.68 and a beta of 0.74.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, meeting the consensus estimate of $1.50. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The company had revenue of $11.46 billion for the quarter, compared to the consensus estimate of $11.80 billion. During the same quarter last year, the company posted $1.34 earnings per share. The company’s revenue for the quarter was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, research analysts predict that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 2.4%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio (DPR) is 67.74%.

Analyst Ratings Changes

ABT has been the subject of several research reports. Raymond James Financial reduced their price target on Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Citigroup dropped their price objective on Abbott Laboratories from $140.00 to $136.00 and set a “buy” rating on the stock in a report on Wednesday, March 11th. Royal Bank Of Canada reduced their target price on shares of Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating for the company in a research note on Friday, January 23rd. Evercore decreased their target price on shares of Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Finally, Piper Sandler dropped their price target on shares of Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating on the stock in a research note on Friday, January 23rd. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and a consensus target price of $136.16.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.